Additionally, it is important to note that recent evidence categorizes CAD as a distinct clinicopathological entity characterized by a clonal, low‐grade lymphoproliferative disorder in the bone marrow, leading to the production of monoclonal autoantibodies, typically of the IgM class [3]. The gene discussed is CD40LG; the disease is cold agglutinin disease.